Previous Study: TRIO013
Next Study: TRIO015
Studies & Results
TRIO014
A randomized, double-blind, placebo controlled, multi-center, Phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor Type 1 receptor (IGF-1R) to first-line chemotherapy in patients with optimally debulked (< 1cm) epithelial ovarian cancer
View FDA Study View EU Study
Presentations
ASCO Annual Meeting, 2014
Konecny GE, Haluska P, Janicke F, et al
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ASCO Annual Meeting, 2014
Konecny GE, Haluska P, Janicke F, et al
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org